Pyörny Joonas, Luukinen Patrick, Sletten Ida Neergård, Reito Aleksi, Leppänen Olli V, Jokihaara Jarkko
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Center for Musculoskeletal Diseases, Tampere University Hospital, Tampere, Finland.
Clin Orthop Relat Res. 2024 May 1;482(5):843-853. doi: 10.1097/CORR.0000000000002906. Epub 2023 Nov 3.
Replantation is an established treatment for traumatic upper extremity amputation. Only a few studies, however, have assessed the patient-reported outcomes of replantation, and the findings of these studies have been conflicting.
QUESTIONS/PURPOSES: (1) Is replantation associated with better hand function than revision amputation? (2) Is replantation associated with better health-related quality of life, less painful cold intolerance, and more pleasing hand esthetics than revision amputation after a traumatic hand amputation?
In this retrospective, comparative study, we collected the details of all patients who sustained a traumatic upper extremity amputation and were treated at the study hospital. Between 2009 and 2019, we treated 2250 patients, and we considered all patients who sustained a traumatic amputation of two or more digital rays or a thumb as potentially eligible. Based on that, 15% (334 of 2250) were eligible; a further 2% (8 of 334) were excluded because of a subsequent new traumatic amputation or bilateral amputation, and another 22% (72 of 334) refused participation, leaving 76% (254 of 334) for analysis here. The primary outcome was the DASH score. Secondary outcomes included health-related quality of life (EuroQOL-5D [EQ-5D-5L] Index), painful cold intolerance (the Cold Intolerance Symptom Severity score), and hand esthetics (the Michigan Hand Questionnaire aesthetic domain score). The minimum follow-up time for inclusion was 18 months. Patients were classified into two treatment groups: replantation (67% [171 of 254], including successful replantation in 84% [144 of 171] and partially successful replantation in 16% [27 of 171], in which some but not all of the replanted tissue survived), and revision (complete) amputation (33% [83 of 254], including primary revision amputation in 70% [58 of 83] and unsuccessful replantation followed by secondary amputation in 30% [25 of 83]). In this cohort, replantation was performed if possible, and the reason for choosing primary revision amputation over replantation was usually an amputated part that was too severely damaged (15% [39 of 254]) or was unattainable (2% [4 of 254]). Some patients (3% [8 of 254]) refused to undergo replantation, or their health status did not allow replantation surgery and postoperative rehabilitation (3% [7 of 254]). Gender, age (mean 48 ± 17 years in the replantation group versus 50 ± 23 years in the revision amputation group; p = 0.41), follow-up time (8 ± 4 years in the replantation group versus 7 ± 4 years in the revision amputation group; p = 0.18), amputation of the dominant hand, smoking, extent of tissue loss, or presence of arterial hypertension did not differ between the groups. Patients in the replantation group less frequently had diabetes mellitus (5% [8 of 171] versus 12% [10 of 83]; p = 0.03) and dyslipidemia (4% [7 of 171] versus 11% [9 of 83]; p = 0.04) than those in the revision group and more often had cut-type injuries (75% [129 of 171] versus 60% [50 of 83]; p = 0.02).
After controlling for potential confounding variables such as age, injury type, extent of tissue loss before treatment, and accident of the dominant hand, replantation was not associated with better DASH scores than revision amputation (OR 0.82 [95% confidence interval (CI) 0.50 to 1.33]; p = 0.42). After controlling for potential cofounding variables, replantation was not associated with better EQ-5D-5L Index scores (OR 0.93 [95% CI 0.56 to 1.55]; p = 0.55), differences in Cold Intolerance Symptom Severity scores (OR 0.85 [95% CI 0.51 to 1.44]; p = 0.79), or superior Michigan Hand Questionnaire esthetic domain scores (OR 0.73 [95% CI 0.43 to 1.26]; p = 0.26) compared with revision amputation.
Replantation surgery was conducted, if feasible, in a homogenous cohort of patients who underwent amputation. If the amputated tissue was too severely damaged or replantation surgery was unsuccessful, the treatment resulted in revision (complete) amputation, which was not associated with worse patient-reported outcomes than successful replantation. These results contradict the assumed benefits of replantation surgery and indicate the need for credible evidence to better guide the care of these patients.
Level III, therapeutic study.
再植术是治疗创伤性上肢截肢的一种既定疗法。然而,仅有少数研究评估了患者报告的再植术结果,且这些研究的结果相互矛盾。
问题/目的:(1)与截肢修复术相比,再植术是否能带来更好的手部功能?(2)与创伤性手部截肢后的截肢修复术相比,再植术是否能带来更好的健康相关生活质量、更少的疼痛性冷不耐受以及更令人满意的手部美观度?
在这项回顾性比较研究中,我们收集了在研究医院接受治疗的所有创伤性上肢截肢患者的详细信息。2009年至2019年间,我们共治疗了2250例患者,我们将所有遭受两根或更多指骨射线或拇指创伤性截肢的患者视为潜在合格患者。基于此,15%(2250例中的334例)符合条件;另有2%(334例中的8例)因随后发生新的创伤性截肢或双侧截肢而被排除,还有22%(334例中的72例)拒绝参与,最终留下76%(334例中的254例)用于本分析。主要结局是DASH评分。次要结局包括健康相关生活质量(欧洲五维健康量表[EQ - 5D - 5L]指数)、疼痛性冷不耐受(冷不耐受症状严重程度评分)以及手部美观度(密歇根手部问卷美学领域评分)。纳入的最短随访时间为18个月。患者被分为两个治疗组:再植术组(67%[254例中的171例],其中84%[171例中的144例]再植成功,16%[171例中的27例]部分成功再植,即部分但并非全部再植组织存活)和截肢修复术(完全)组(33%[254例中的83例],其中70%[83例中的58例]为初次截肢修复术,30%[83例中的25例]为再植失败后二次截肢)。在该队列中,尽可能进行再植术,选择初次截肢修复术而非再植术的原因通常是截肢部分损伤过于严重(15%[254例中的39例])或无法进行再植(2%[254例中的4例])。一些患者(3%[254例中的8例])拒绝接受再植术,或者其健康状况不允许进行再植手术及术后康复(3%[254例中的7例])。两组在性别、年龄(再植术组平均48±17岁,截肢修复术组平均50±23岁;p = 0.41)、随访时间(再植术组8±4年,截肢修复术组7±4年;p = 0.18)、优势手截肢、吸烟、组织丢失程度或动脉高血压的存在情况方面无差异。再植术组患者患糖尿病(5%[171例中的8例]对12%[83例中的10例];p = 0.03)和血脂异常(4%[171例中的7例]对11%[83例中的9例];p = 0.04)的频率低于截肢修复术组,而切割伤类型的损伤更为常见(75%[171例中的129例]对60%[83例中的50例];p = 0.02)。
在控制了年龄、损伤类型、治疗前组织丢失程度以及优势手意外等潜在混杂变量后,与截肢修复术相比,再植术与更好的DASH评分无关(比值比0.82[95%置信区间(CI)0.50至1.33];p = 0.42)。在控制潜在混杂变量后,与截肢修复术相比,再植术与更好的EQ - 5D - 5L指数评分(比值比0.93[95%CI 0.56至1.55];p = 0.55)、冷不耐受症状严重程度评分差异(比值比0.85[95%CI 0.51至1.44];p = 0.79)或更优的密歇根手部问卷美学领域评分(比值比0.73[95%CI 0.43至1.26];p = 0.26)均无关。
在接受截肢手术的同质患者队列中,若可行则进行再植手术。如果截肢组织损伤过于严重或再植手术失败,治疗结果为截肢修复术(完全),这与成功再植术相比,患者报告的结局并不更差。这些结果与再植手术假定的益处相矛盾,表明需要可靠证据来更好地指导这些患者的治疗。
III级,治疗性研究。